磷酸西格列汀为DPP-4抑制剂，临床上主要用于改善2型糖尿病患者的血糖控制。本次国药威奇达的磷 酸西格列汀原料药获得《化学原料药上市申请批准通知书》，表明该原料药符合国内药品注册的有关规 定要求，可以在国内市场进行销售，将进一步丰富公司特色专科原料药产品群。 国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团威奇达药业有限公司(简称国药威奇达) 收到国家药品监督管理局关于原料药磷酸西格列汀的《化学原料药上市申请批准通知书》。 ...

Core Viewpoint - Gannee Pharmaceutical's stock price increased by 1.05% to 64.36 yuan as of August 6, 2025, with a notable intraday rebound and a peak of 65.90 yuan [1] Company Overview - Gannee Pharmaceutical specializes in the biopharmaceutical sector, focusing on the research, production, and sales of diabetes treatment drugs, including insulin analogs and human insulin [1] Market Performance - The trading volume on August 6 reached 1.322 billion yuan, with a turnover rate of 3.65% [1] - The net inflow of main funds on August 6 was 69.8268 million yuan, with a cumulative net inflow of 153 million yuan over the past five days [1] - The current total market capitalization of the company is 38.685 billion yuan, while the circulating market value stands at 36.132 billion yuan [1]